Company facts
- Founded
- 2021
- Headquarters
- Switzerland
About
Ymmunobio has identified a new tumor marker with superior properties: 1. It is present in at least 13 solid tumors 2. It has a prevalence of up to 98% in cancer patients 3. It is not expressed by normal tissue Ymmunobio has built a complete development program around this novel target featuring three therapeutic antibo…